Nuance Pharma Announces NMPA Acceptance of NDA for Ohtuvayre (Ensifentrine) for COPD Maintenance Treatment in China
Tuesday, January 27, 2026
Nuance Pharma, a leading innovation-focused biopharmaceutical company in Asia Pacific, has achieved a significant regulatory milestone with the official acceptance of its New Drug Application (NDA) for Ohtuvayre® (ensifentrine) by the National Medical Products Administration (NMPA) of China. This application targets the maintenance treatment of chronic obstructive pulmonary disease (COPD), a condition affecting millions in the region and representing a major unmet need in respiratory care. The acceptance marks a critical step forward in bringing this first-in-class therapy to the Chinese market, potentially redefining treatment paradigms for COPD patients.
The NDA submission follows the successful completion of the Phase 3 registrational ENHANCE-CHINA study, which demonstrated positive results supporting the efficacy and safety of ensifentrine. This novel inhaled therapy acts as a dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4), offering a unique mechanism that improves lung function, reduces exacerbations, and enhances quality of life without the steroid-related side effects common in existing treatments. Nuance Pharma's strategic focus on specialty care, including respiratory diseases, positions this asset as a cornerstone of its pipeline, aligning with broader industry trends toward biopharma innovations and novel delivery mechanisms in Asia.
Mark Lotter, Founder and Chief Executive Officer of Nuance Pharma, expressed enthusiasm about the development, stating, "We are very pleased to see the NDA for Ohtuvayre® has been officially accepted in mainland China. This exciting milestone affirms our confidence in ensifentrine’s potential to re-define the COPD treatment in China." The company's commitment extends to expanding access, leveraging ongoing early access programs in Hainan BoAo and the Greater Bay Area, as well as recent regulatory approval in Macau. These initiatives underscore Nuance's Dual Wheel model, which balances innovative pipeline development with sustainable commercial operations across China and Asia Pacific.
Charlie Chen, Chief Operating Officer, highlighted the timely nature of the submission: "The NDA submission was completed as planned following the positive results from the Phase 3 registrational ENHANCE-CHINA study. Following our ongoing early access programs in Hainan BoAo and Greater Bay Area, as well as regulatory approval in Macau, we look forward to accelerating patient access to this innovative medicine in China." This progress reflects China's evolving regulatory landscape, which is increasingly supportive of innovative therapies through streamlined review processes and alignment with international standards.
Nuance Pharma's mission to address critical unmet medical needs in Asia Pacific is exemplified by its diversified portfolio spanning respiratory, pain management, emergency care, and iron deficiency anemia. The company's emphasis on late-stage clinical assets and commercialized products positions it as a key player in the biopharma sector. In the context of China's booming biopharmaceutical ecosystem, where biologics and novel drugs now constitute about 40% of development pipelines, Nuance's advancements contribute to the nation's rise as a global hub for clinical trials—accounting for around 30% of worldwide activity.
This regulatory acceptance also highlights strategic partnerships and licensing agreements, with a third of global deals by multinational pharma firms involving Chinese businesses in the first half of 2025. For industry executives, this development signals opportunities in respiratory biopharma, potential market entry strategies, and the impact of NMPA's expedited reviews on R&D timelines. As Nuance advances toward potential approval, it reinforces investor confidence in Asia-focused innovations amid geopolitical shifts and tariff considerations affecting supply chains.
Looking ahead, the forward-looking trajectory includes expanded clinical access and commercialization efforts, potentially transforming COPD management in China. Nuance's integrated approach—combining global-leading pipelines with regional operations—exemplifies executive-level strategies for sustainable growth in competitive markets. Stakeholders in clinical trials, bio pharma, and regulatory affairs will monitor this closely, as it could set precedents for future NDA successes in specialty care.
The announcement arrives at a pivotal time for Asia's pharma landscape, where production growth in China is forecasted at 6.6% for 2026, driven by biopharma shifts and R&D investments. Nuance's milestone bolsters the sector's resilience, supported by policy incentives for innovation hubs like Pudong, Shanghai. This positions Ohtuvayre as a flagship example of how targeted therapies can navigate regulatory hurdles while addressing high-prevalence diseases, ultimately benefiting healthcare systems and manufacturers alike through diversified portfolios and efficient development paths.
